Lyell Immunopharma to acquire ImmPACT—are CAR T-cell therapies the future of oncology?

Lyell Immunopharma is making waves with its strategic acquisition of ImmPACT Bio, a move aimed at bolstering its T-cell therapy capabilities. The transaction, valued at ... Read More